Apogenix biomarker pinpoints responders to glioblastoma drug
Apogenix GmbH is meeting officials from three of Europe’s leading national drug regulators in the coming weeks to evaluate whether they will support a bid to obtain conditional marketing approval for its glioblastoma drug APG101, following a fresh biomarker analysis, which shows that the therapy offers likely responders a 10-month survival benefit. The Heidelberg, Germany-based firm unveiled the new analysis at the J.P. Morgan Healthcare Conference in San Francisco, where it is drumming up interest from investors and potential partners alike.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST